Showing 4491-4500 of 8828 results for "".
- ASDS News: CellFX Clears Low-Risk Basal Cell Carcinoma Lesionshttps://practicaldermatology.com/news/asds-news-cellfx-clears-low-risk-basal-cell-carcinoma-lesions/2461374/CellFX procedure is effective for low-risk superficial and nodular basal cell carcinoma lesion clearance, according to research presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. "It is exciting and encouraging to see complete clearance of b
- National Physician Assistant Week Celebrates Work of PAshttps://practicaldermatology.com/news/national-physician-assistant-week-celebrates-work-of-pas/2461373/The American Academy of Physician Associates (AAPA) is celebrating National Physician Assistant Week October 6-12 to recognize the PA profession and its contributions to the nation’s health. This PA Week, the AAPA wants to spread the word: PAs Go Beyond! Do you know a PA who goes beyond? Th
- Candesant Biomedical Introduces New SweatTech Initiative at ASDShttps://practicaldermatology.com/news/candesant-biomedical-novel-investigational-technology-for-hyperhydrosis/2461371/Candesant Biomedical is introducing a new initiative – SweatTech™ – at the ASDS annual meeting. The company is also developing a new novel technology (currently under FDA review) that reduces axillary hyperhidrosis. Their “TAT” (targeted alkali thermolysis) pat
- NEA Introduces New “Focus on Eczema” Campaign for Eczema Awareness Month 2022https://practicaldermatology.com/news/nea-introduces-new-focus-on-eczema-campaign/2461367/The National Eczema Association (NEA) is rolling out its annual
- Johnson & Johnson Announces Kenvue as the Name for New Consumer Health Companyhttps://practicaldermatology.com/news/johnson-johnson-announces-kenvue-as-the-name-for-new-consumer-health-company/2461363/Johnson & Johnson’s planned new consumer health company will be named...Kenvue. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” ref
- Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial of EVO101 in ADhttps://practicaldermatology.com/news/evommune-initiates-phase-2a-proof-of-concept-clinical-trial-of-evo101-in-ad/2461362/Evommune, Inc. enrolled the first patient in a Phase 2a proof-of-concept clinical trial evaluating EVO101, a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), in patients with atopic dermatitis (AD). The Phase 2a trial is a randomized, double-bl
- Positive Topline Results from Pivotal Phase 3 Trial of Arcutis Biotherapeutics' Roflumilast Foam in Scalp and Body Psoriasishttps://practicaldermatology.com/news/positive-topline-results-from-pivotal-phase-3-trial-of-arctuis-biotherapeutics-roflumilast-foam-in-scalp-and-body-psoriasis/2461359/Topline results from the ARRECTOR Pivotal Phase 3 trial evaluating Arcutis Biotherapeutics, Inc.'s roflumilast foam 0.3% were positive for the treatment of adults and adolescents with scalp and body psoriasis. The study met its co-primary endpoints of S-
- Investigational Cannabinoid Receptor Agonist Proves Safe and Effective in Amyopathic Dermatomyositishttps://practicaldermatology.com/news/investigational-cannabinoid-receptor-agonist-proves-safe-and-effective-in-amyopathic-dermatomyositis/2461357/Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, a new study in the Journal of Investigative Dermatology suggests. This phase 2 trial, the
- Ortho Dermatologics Names 2022 Aspire Higher Scholarship Recipientshttps://practicaldermatology.com/news/ortho-dermatologics-names-2022-aspire-higher-scholarship-recipients/2461356/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, recently named the recipients of their 2022 Aspire Higher Scholarship program. The program, which has provided a total of $918,000 in scholarships since launching in 2013, will award nine students who have been treate
- EMA Accepts Marketing Authorization Applications for UCB's Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritishttps://practicaldermatology.com/news/ema-accepts-marketing-authorization-applications-for-ucbs-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis/2461354/The European Medicines Agency (EMA) has accepted for regulatory review the two marketing authorization applications for UCB's bimekizumab for the treatment of adult patients with active psoriatic arthritis (PsA), and adult patients with active axial spondyloarthritis (axSpA). &ldquo